{"title":"新诊断的转移性前列腺癌治疗的新进展","authors":"Gianmarco Leone, C. Alifrangis","doi":"10.1002/tre.916","DOIUrl":null,"url":null,"abstract":"The treatment algorithm for metastatic prostate cancer has changed more in the last decade than in the previous 50 years. Testosterone suppression has for many years been the gold standard for men newly diagnosed with prostate cancer. However, randomised studies have now shown that escalation of therapy beyond testosterone depletion results in profound and clinically meaningful survival benefits. This review aims to summarise the latest advancement in the field focusing on treatment of newly diagnosed hormone‐sensitive prostate cancer.","PeriodicalId":42819,"journal":{"name":"Trends in Urology & Mens Health","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New developments in the management of newly diagnosed metastatic prostate cancer\",\"authors\":\"Gianmarco Leone, C. Alifrangis\",\"doi\":\"10.1002/tre.916\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment algorithm for metastatic prostate cancer has changed more in the last decade than in the previous 50 years. Testosterone suppression has for many years been the gold standard for men newly diagnosed with prostate cancer. However, randomised studies have now shown that escalation of therapy beyond testosterone depletion results in profound and clinically meaningful survival benefits. This review aims to summarise the latest advancement in the field focusing on treatment of newly diagnosed hormone‐sensitive prostate cancer.\",\"PeriodicalId\":42819,\"journal\":{\"name\":\"Trends in Urology & Mens Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Urology & Mens Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/tre.916\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Urology & Mens Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/tre.916","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
New developments in the management of newly diagnosed metastatic prostate cancer
The treatment algorithm for metastatic prostate cancer has changed more in the last decade than in the previous 50 years. Testosterone suppression has for many years been the gold standard for men newly diagnosed with prostate cancer. However, randomised studies have now shown that escalation of therapy beyond testosterone depletion results in profound and clinically meaningful survival benefits. This review aims to summarise the latest advancement in the field focusing on treatment of newly diagnosed hormone‐sensitive prostate cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
